Immune Thrombocytopenia-A Neglected Adverse Event of PD-1 and PD-L1 Inhibitors in Clinical Trials
JAMA Oncol
.
2019 Nov 1;5(11):1640-1641.
doi: 10.1001/jamaoncol.2019.3599.
Authors
Xiaocong Pang
1
,
Xian Su
2
,
Yimin Cui
1
Affiliations
1
Department of Pharmacy, Peking University First Hospital, Beijing, China.
2
Centre for Drug Evaluation, National Medical Products Administration, Beijing, China.
PMID:
31536124
DOI:
10.1001/jamaoncol.2019.3599
No abstract available